{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:18Z","timestamp":1791593838254,"version":"4.3.4"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40259-024-00701-1","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T01:23:55Z","timestamp":1737941035000},"page":"185-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-068X","authenticated-orcid":false,"given":"Lea","family":"Gerischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5381-5995","authenticated-orcid":false,"given":"Paolo","family":"Doksani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-2594","authenticated-orcid":false,"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"701_CR1","first-page":"1","volume":"32","author":"F Jolly","year":"1895","unstructured":"Jolly F. Ueber Myasthenia gravis pseudoparalytica. Berliner Klinische Wochenschrift. 1895;32:1\u20136.","journal-title":"Berliner Klinische Wochenschrift."},{"issue":"2","key":"701_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"key":"701_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","volume":"1","author":"MB Walker","year":"1934","unstructured":"Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet. 1934;1:1200\u20131.","journal-title":"Lancet"},{"issue":"6","key":"701_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp.27.6.485","volume":"27","author":"JA Simpson","year":"1964","unstructured":"Simpson JA. Immunological disturbances in myasthenia gravis with a report of Hashimoto\u2019s disease developing after thymectomy. J Neurol Neurosurg Psychiatry. 1964;27(6):485\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"701_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"issue":"12","key":"701_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"701_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"2","key":"701_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185\u201396.","journal-title":"Muscle Nerve"},{"issue":"10","key":"701_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069\u201377.","journal-title":"Neurology"},{"issue":"4","key":"701_CR10","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376\u201389.","journal-title":"Neurology"},{"issue":"11","key":"701_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105\u201312.","journal-title":"JAMA Neurol"},{"issue":"12","key":"701_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"701_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"issue":"6","key":"701_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909\u201317.","journal-title":"Muscle Nerve"},{"issue":"1","key":"701_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841(1):769\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"701_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553\u201362.","journal-title":"Muscle Nerve"},{"issue":"7","key":"701_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"issue":"6","key":"701_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54(6):1015\u201322.","journal-title":"Muscle Nerve"},{"issue":"2","key":"701_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957\u201363.","journal-title":"Muscle Nerve"},{"issue":"5","key":"701_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","volume":"49","author":"HD Katzberg","year":"2014","unstructured":"Katzberg HD, Barnett C, Merkies IS, Bril V. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):661\u20135.","journal-title":"Muscle Nerve"},{"issue":"5","key":"701_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, Mg C. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331.","journal-title":"Muscle Nerve"},{"issue":"1","key":"701_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/ard.2004.023028","volume":"64","author":"F Tubach","year":"2005","unstructured":"Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"701_CR23","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617\u201328.","journal-title":"Neurology"},{"issue":"7","key":"701_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16280","volume":"31","author":"A Meisel","year":"2024","unstructured":"Meisel A, Sacca F, Spillane J, Vissing J, Sub-committee MGC. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol. 2024;31(7): e16280.","journal-title":"Eur J Neurol"},{"issue":"2","key":"701_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163\u201375.","journal-title":"Lancet Neurol"},{"issue":"6","key":"701_CR26","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"issue":"2","key":"701_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","volume":"80","author":"F Baggi","year":"2013","unstructured":"Baggi F, Andreetta F, Maggi L, Confalonieri P, Morandi L, Salerno F, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80(2):188\u201395.","journal-title":"Neurology"},{"issue":"6","key":"701_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis. Muscle Nerve. 2016;54(6):1041\u20139.","journal-title":"Muscle Nerve"},{"issue":"2","key":"701_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176\u201388.","journal-title":"Lancet Neurol"},{"issue":"7","key":"701_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459\u201367.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"701_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","volume":"139","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann S, Harms L, Schuelke M, Ruckert JC, Goebel HH, Stenzel W, et al. Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol. 2020;139(6):1119\u201322.","journal-title":"Acta Neuropathol"},{"key":"701_CR32","volume":"2011","author":"MF Finnis","year":"2011","unstructured":"Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011: 404101.","journal-title":"Autoimmune Dis."},{"issue":"1","key":"701_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","volume":"14","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Masuda M, Uzawa A, Nagane Y, Konno S, Suzuki Y, et al. Japan MG registry: chronological surveys over 10 years. Clin Experiment Neuroimmunol. 2022;14(1):5\u201312.","journal-title":"Clin Experiment Neuroimmunol."},{"issue":"4","key":"701_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/00207454.2018.1529669","volume":"129","author":"A Asmail","year":"2019","unstructured":"Asmail A, Kesler A, Kolb H, Drory VE, Karni A. A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences. Int J Neurosci. 2019;129(4):313\u20139.","journal-title":"Int J Neurosci"},{"issue":"1","key":"701_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mus.26104","volume":"58","author":"I Lee","year":"2018","unstructured":"Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. Muscle Nerve. 2018;58(1):90\u20138.","journal-title":"Muscle Nerve"},{"key":"701_CR36","doi-asserted-by":"crossref","unstructured":"Beland B, Perera T, Lee A, Greenfield J, Korngut L, Jewett G. No sex-based differences in odds of starting or time to treatment of generalized myasthenia gravis: a single center cohort study. Muscle Nerve. 2024;n\/a(n\/a).","DOI":"10.1002\/mus.28210"},{"issue":"8","key":"701_CR37","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1007\/s00415-024-12490-2","volume":"271","author":"M Funke","year":"2024","unstructured":"Funke M, Eveslage M, Zschuntzsch J, Hagenacker T, Ruck T, Schubert C, et al. Fatigue and associated factors in myasthenia gravis: a nationwide registry study. J Neurol. 2024;271(8):5665\u201370.","journal-title":"J Neurol"},{"key":"701_CR38","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.","journal-title":"Ther Adv Neurol Disord"},{"key":"701_CR39","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"key":"701_CR40","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"701_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189\u2013202.","journal-title":"Lancet Neurol"},{"issue":"8","key":"701_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"6","key":"701_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023;94(6):467\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"701_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19\u201327.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"3","key":"701_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","volume":"23","author":"P Narayanaswami","year":"2024","unstructured":"Narayanaswami P, Sanders DB, Thomas L, Thibault D, Blevins J, Desai R, et al. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol. 2024;23(3):267\u201376.","journal-title":"Lancet Neurol"},{"issue":"6","key":"701_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"701_CR47","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","volume":"124","author":"JL De Bleecker","year":"2024","unstructured":"De Bleecker JL, Remiche G, Alonso-Jimenez A, Van Parys V, Bissay V, Delstanche S, et al. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg. 2024;124(4):1371\u201383.","journal-title":"Acta Neurol Belg"},{"issue":"5\u20136","key":"701_CR48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5\u20136):428\u201335.","journal-title":"Autoimmunity"},{"issue":"1","key":"701_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","volume":"4","author":"LL Kusner","year":"2008","unstructured":"Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol. 2008;4(1):43\u201352.","journal-title":"Expert Rev Clin Immunol"},{"key":"701_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther. 2023;12:25\u201345.","journal-title":"Immunotargets Ther."},{"issue":"1","key":"701_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14\u201324.","journal-title":"Muscle Nerve"},{"issue":"8","key":"701_CR52","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","volume":"28","author":"H Andersen","year":"2019","unstructured":"Andersen H, Mantegazza R, Wang JJ, O\u2019Brien F, Patra K, Howard JF Jr, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019;28(8):2247\u201354.","journal-title":"Qual Life Res"},{"issue":"2","key":"701_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve. 2021;64(2):212\u20135.","journal-title":"Muscle Nerve"},{"issue":"9","key":"701_CR54","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","volume":"268","author":"U Hofstadt-van Oy","year":"2021","unstructured":"Hofstadt-van Oy U, Stankovic S, Kelbel C, Oswald D, Larrosa-Lombardi S, Barchfeld T, et al. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol. 2021;268(9):3125\u20138.","journal-title":"J Neurol"},{"issue":"10","key":"701_CR55","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","volume":"44","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A, Iovino A, Piscosquito G, Calicchio G, et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. 2023;44(10):3707\u20139.","journal-title":"Neurol Sci"},{"key":"701_CR56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","volume":"156","author":"JF Brandsema","year":"2024","unstructured":"Brandsema JF, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao VK, et al. Eculizumab in adolescent patients with refractory generalized myasthenia gravis: a phase 3, open-label, multicenter study. Pediatr Neurol. 2024;156:198\u2013207.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"701_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909.","journal-title":"PLoS ONE"},{"issue":"5","key":"701_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):66.","journal-title":"NEJM Evid."},{"issue":"5","key":"701_CR59","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mus.28044","volume":"69","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Mantegazza R, Kushlaf H, Suzuki S, Wiendl H, et al. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: a post hoc subgroup analysis of the CHAMPION MG study. Muscle Nerve. 2024;69(5):556\u201365.","journal-title":"Muscle Nerve"},{"issue":"12","key":"701_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16490","volume":"31","author":"AA Habib","year":"2024","unstructured":"Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M, et al. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Eur J Neurol. 2024;31(12): e16490.","journal-title":"Eur J Neurol"},{"issue":"1","key":"701_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M. Zilucoplan: first approval. Drugs. 2024;84(1):99\u2013104.","journal-title":"Drugs"},{"issue":"5","key":"701_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"key":"701_CR63","doi-asserted-by":"publisher","first-page":"175628642412431","DOI":"10.1177\/17562864241243186","volume":"17","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, et al. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024;17:17562864241243186.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"701_CR64","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1007\/s00415-024-12209-3","volume":"271","author":"MD Weiss","year":"2024","unstructured":"Weiss MD, Freimer M, Leite MI, Maniaol A, Utsugisawa K, Bloemers J, et al. Improvement of fatigue in generalised myasthenia gravis with zilucoplan. J Neurol. 2024;271(5):2758\u201367.","journal-title":"J Neurol"},{"key":"701_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","volume":"165","author":"S Jindal","year":"2024","unstructured":"Jindal S, Pedersen DV, Gera N, Chandler J, Patel R, Neill A, et al. Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. 2024;165:29\u201341.","journal-title":"Mol Immunol"},{"issue":"6","key":"701_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269749","volume":"17","author":"K Devalaraja-Narashimha","year":"2022","unstructured":"Devalaraja-Narashimha K, Huang C, Cao M, Chen YP, Borodovsky A, Olson WC, et al. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS ONE. 2022;17(6): e0269749.","journal-title":"PLoS ONE"},{"issue":"16","key":"701_CR67","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40265-023-01955-9","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Pozelimab: first approval. Drugs. 2023;83(16):1551\u20137.","journal-title":"Drugs"},{"key":"701_CR68","doi-asserted-by":"crossref","unstructured":"Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2024.","DOI":"10.1056\/NEJMoa2410316"},{"issue":"16","key":"701_CR69","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"701_CR70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","volume":"138","author":"M Harboe","year":"2004","unstructured":"Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138(3):439\u201346.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"701_CR71","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","volume":"30","author":"TT Kuo","year":"2010","unstructured":"Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777\u201389.","journal-title":"J Clin Immunol"},{"key":"701_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074","volume":"430","author":"GI Wolfe","year":"2021","unstructured":"Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, et al. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021;430: 118074.","journal-title":"J Neurol Sci"},{"issue":"7","key":"701_CR73","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"5","key":"701_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Li G, Korobko D, Smilowski M, Liu L, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024;21(5): e00378.","journal-title":"Neurotherapeutics"},{"key":"701_CR75","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.nmd.2023.07.443","volume":"33","author":"K Musick","year":"2023","unstructured":"Musick K, Howard J, Li G, Vu T, Korobko D, Smilowski M, et al. P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+. Neuromuscul Disord. 2023;33:S179.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"701_CR76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"6","key":"701_CR77","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"issue":"5","key":"701_CR78","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, Tan X, Wang S, Qu R, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298\u2013308.","journal-title":"J Neurol"},{"issue":"4","key":"701_CR79","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R, et al. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2024;81(4):336\u201345.","journal-title":"JAMA Neurol"},{"issue":"1","key":"701_CR80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/acn3.51946","volume":"11","author":"RJ Nowak","year":"2024","unstructured":"Nowak RJ, Breiner A, Bril V, Allen JA, Khan S, Levine T, et al. Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension. Ann Clin Transl Neurol. 2024;11(1):194\u2013206.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"701_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000536","volume":"6","author":"M Benatar","year":"2024","unstructured":"Benatar M, Wiendl H, Nowak R, Zheng Y, Macias W. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol Open. 2024;6(1): e000536.","journal-title":"BMJ Neurol Open."},{"issue":"2","key":"701_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and Efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG Study. Neurology. 2024;102(2): e207937.","journal-title":"Neurology"},{"issue":"4","key":"701_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-023-01383-4","volume":"47","author":"LV Rindi","year":"2024","unstructured":"Rindi LV, Zace D, Braccialarghe N, Massa B, Barchi V, Iannazzo R, et al. Drug-induced progressive multifocal leukoencephalopathy (PML): a systematic review and meta-analysis. Drug Saf. 2024;47(4):333\u201354.","journal-title":"Drug Saf"},{"issue":"9","key":"701_CR84","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156\u201364.","journal-title":"Arch Neurol"},{"key":"701_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejpn.2022.06.009","volume":"40","author":"S Ramdas","year":"2022","unstructured":"Ramdas S, Della Marina A, Ryan MM, McWilliam K, Klein A, Jacquier D, et al. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review. Eur J Paediatr Neurol. 2022;40:5\u201310.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"701_CR86","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"701_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.736190","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Pu M, Chen D, Shi J, Li Z, Guo J, et al. Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis. Front Neurol. 2021;12: 736190.","journal-title":"Front Neurol"},{"issue":"8","key":"701_CR88","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77(8):974\u201381.","journal-title":"JAMA Neurol"},{"issue":"3","key":"701_CR89","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3233\/JND-170211","volume":"4","author":"A Russell","year":"2017","unstructured":"Russell A, Yaraskavitch M, Fok D, Chhibber S, Street L, Korngut L. Obinutuzumab plus chlorambucil in a patient with severe myasthenia gravis and chronic lymphocytic leukemia. J Neuromuscul Dis. 2017;4(3):251\u20137.","journal-title":"J Neuromuscul Dis."},{"issue":"6","key":"701_CR90","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1002\/mus.26707","volume":"60","author":"MJ Waters","year":"2019","unstructured":"Waters MJ, Field D, Ravindran J. Refractory myasthenia gravis successfully treated with ofatumumab. Muscle Nerve. 2019;60(6):E45\u20137.","journal-title":"Muscle Nerve"},{"issue":"2","key":"701_CR91","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","volume":"267","author":"F Scheibe","year":"2020","unstructured":"Scheibe F, Ostendorf L, Reincke SM, Pruss H, von Brunneck AC, Kohnlein M, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. J Neurol. 2020;267(2):317\u201323.","journal-title":"J Neurol"},{"issue":"12","key":"701_CR92","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149\u201355.","journal-title":"N Engl J Med"},{"issue":"6","key":"701_CR93","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/ene.15266","volume":"29","author":"F Scheibe","year":"2022","unstructured":"Scheibe F, Ostendorf L, Pruss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847\u201354.","journal-title":"Eur J Neurol"},{"key":"701_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2023-001112","volume":"11","author":"SRP McDonnell","year":"2024","unstructured":"McDonnell SRP, Nguyen VA, Walton NM, Merkwirth C, Hong F, Berg D, et al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci Med. 2024;11:1.","journal-title":"Lupus Sci Med."},{"issue":"5","key":"701_CR95","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431\u201340.","journal-title":"Lancet Oncol"},{"issue":"5","key":"701_CR96","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","volume":"29","author":"N Khalesi","year":"2021","unstructured":"Khalesi N, Korani S, Korani M, Johnston TP, Sahebkar A. Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases. Inflammopharmacology. 2021;29(5):1291\u2013306.","journal-title":"Inflammopharmacology"},{"issue":"3","key":"701_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","volume":"193","author":"AM Gomez","year":"2014","unstructured":"Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A, et al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol. 2014;193(3):1055\u201363.","journal-title":"J Immunol"},{"issue":"10","key":"701_CR98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","volume":"10","author":"C Schneider-Gold","year":"2017","unstructured":"Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R. Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. Ther Adv Neurol Disord. 2017;10(10):339\u201341.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"701_CR99","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12883-020-01813-1","volume":"20","author":"S Sakano","year":"2020","unstructured":"Sakano S, Matsuyama H, Ishikawa H, Shindo A, Ii Y, Matsuura K, et al. Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report. BMC Neurol. 2020;20(1):240.","journal-title":"BMC Neurol"},{"issue":"1","key":"701_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024523","volume":"9","author":"S Kohler","year":"2019","unstructured":"Kohler S, Marschenz S, Grittner U, Alexander T, Hiepe F, Meisel A. Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open. 2019;9(1): e024523.","journal-title":"BMJ Open"},{"issue":"1","key":"701_CR101","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T Kumpfel","year":"2024","unstructured":"Kumpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Haussler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"12","key":"701_CR102","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364.","journal-title":"Drugs"},{"issue":"10206","key":"701_CR103","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"3","key":"701_CR104","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","volume":"17","author":"P Schneider","year":"2005","unstructured":"Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17(3):282\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"701_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nbt.2076","volume":"30","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69\u201377.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"701_CR106","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253\u201365.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"701_CR107","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"701_CR108","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","volume":"7","author":"J Chan","year":"2023","unstructured":"Chan J, Walters GD, Puri P, Jiang SH. Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol. 2023;7(1):37.","journal-title":"BMC Rheumatol."},{"issue":"16","key":"701_CR109","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","journal-title":"Neurology"},{"issue":"14","key":"701_CR110","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671\u20135.","journal-title":"Drugs"},{"issue":"8","key":"701_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, et al. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024;31(8): e16322.","journal-title":"Eur J Neurol"},{"issue":"9","key":"701_CR112","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729\u201338.","journal-title":"Lancet Neurol"},{"issue":"8","key":"701_CR113","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/all.15261","volume":"77","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Brasileiro A, Kolkhir P, Frischbutter S, Scheffel J, Monino-Romero S, et al. Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355\u201366.","journal-title":"Allergy"},{"key":"701_CR114","doi-asserted-by":"publisher","first-page":"1280226","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, Ni H, et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol. 2023;14:1280226.","journal-title":"Front Immunol"},{"issue":"5","key":"701_CR115","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"key":"701_CR116","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","volume":"27","author":"K Rejdak","year":"2019","unstructured":"Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117\u201320.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"701_CR117","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/ene.14124","volume":"27","author":"K Rejdak","year":"2020","unstructured":"Rejdak K, Szklener S, Korchut A, Baranowski D. Cladribine in myasthenia gravis: a pilot open-label study. Eur J Neurol. 2020;27(3):586\u20139.","journal-title":"Eur J Neurol"},{"issue":"5","key":"701_CR118","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1002\/mus.26446","volume":"59","author":"G Laureys","year":"2019","unstructured":"Laureys G, De Bleecker JL. Cladribine in myasthenia gravis: a case urging for prudence. Muscle Nerve. 2019;59(5):E38.","journal-title":"Muscle Nerve"},{"issue":"12","key":"701_CR119","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1111\/ajt.14872","volume":"18","author":"J Ristov","year":"2018","unstructured":"Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895\u2013904.","journal-title":"Am J Transplant"},{"key":"701_CR120","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","volume":"119","author":"B GomezMancilla","year":"2024","unstructured":"GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espie P, Dupuy C, et al. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study. J Clin Neurosci. 2024;119:76\u201384.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"701_CR121","volume":"16","author":"BR Meher","year":"2024","unstructured":"Meher BR, Mohanty RR, Dash A. Review of satralizumab for neuromyelitis optica spectrum disorder: a new biologic agent targeting the interleukin-6 receptor. Cureus. 2024;16(2): e55100.","journal-title":"Cureus."},{"issue":"6","key":"701_CR122","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395\u2013412.","journal-title":"Nat Rev Drug Discov"},{"key":"701_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358: 577634.","journal-title":"J Neuroimmunol"},{"key":"701_CR124","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/JIR.S423098","volume":"16","author":"TT Yang","year":"2023","unstructured":"Yang TT, Wang ZY, Fan ZX, Yuan BY, Ma L, Lu JF, et al. A pilot study on tocilizumab in very-late-onset myasthenia gravis. J Inflamm Res. 2023;16:5835\u201343.","journal-title":"J Inflamm Res"},{"issue":"2","key":"701_CR125","doi-asserted-by":"publisher","first-page":"824","DOI":"10.14336\/AD.2023.0528","volume":"15","author":"D Jia","year":"2024","unstructured":"Jia D, Zhang F, Li H, Shen Y, Jin Z, Shi FD, et al. Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized myasthenia gravis. Aging Dis. 2024;15(2):824\u201330.","journal-title":"Aging Dis"},{"issue":"6","key":"701_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14793","volume":"30","author":"Z Ruan","year":"2024","unstructured":"Ruan Z, Tang Y, Gao T, Li C, Guo R, Sun C, et al. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. CNS Neurosci Ther. 2024;30(6): e14793.","journal-title":"CNS Neurosci Ther"},{"key":"701_CR127","first-page":"2","volume":"10","author":"A Mariottini","year":"2023","unstructured":"Mariottini A, Bulgarini G, Cornacchini S, Damato V, Saccardi R, Massacesi L. Hematopoietic stem cell transplantation for the treatment of autoimmune neurological diseases: an update. Bioengineering (Basel). 2023;10:2.","journal-title":"Bioengineering (Basel)."},{"issue":"1","key":"701_CR128","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nmd.2016.09.020","volume":"27","author":"I Hakansson","year":"2017","unstructured":"Hakansson I, Sandstedt A, Lundin F, Askmark H, Pirskanen R, Carlson K, et al. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis\u2014a case report. Neuromuscul Disord. 2017;27(1):90\u20133.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"701_CR129","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","volume":"73","author":"A Bryant","year":"2016","unstructured":"Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016;73(6):652\u20138.","journal-title":"JAMA Neurol"},{"issue":"2","key":"701_CR130","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nmd.2018.11.008","volume":"29","author":"CL Sossa Melo","year":"2019","unstructured":"Sossa Melo CL, Pena AM, Salazar LA, Jimenez SI, Gomez ED, Chalela CM, et al. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: a case report. Neuromuscul Disord. 2019;29(2):142\u20135.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"701_CR131","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/mus.27772","volume":"67","author":"B Beland","year":"2023","unstructured":"Beland B, Hahn C, Jamani K, Chhibber S, White C, Atkins H, et al. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies. Muscle Nerve. 2023;67(2):154\u20137.","journal-title":"Muscle Nerve"},{"issue":"11","key":"701_CR132","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/acn3.51898","volume":"10","author":"MI Schlatter","year":"2023","unstructured":"Schlatter MI, Yandamuri SS, O\u2019Connor KC, Nowak RJ, Pham MC, Obaid AH, et al. Remission of severe myasthenia gravis after autologous stem cell transplantation. Ann Clin Transl Neurol. 2023;10(11):2105\u201313.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"701_CR133","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.humimm.2010.01.013","volume":"71","author":"C Deligny","year":"2010","unstructured":"Deligny C, Clave E, Sibon D, Daikeler T, Keshmandt H, Carmagnat M, et al. New onset of myasthenia gravis after treatment of systemic sclerosis by autologous hematopoietic stem cell transplantation: sustained autoimmunity or inadequate reset of tolerance? Hum Immunol. 2010;71(4):363\u20135.","journal-title":"Hum Immunol"},{"key":"701_CR134","doi-asserted-by":"crossref","unstructured":"Pecher AC, Hensen L, Lengerke C, Henes J. The future of CAR T therapeutics to treat autoimmune disorders. Mol Diagn Ther. 2024.","DOI":"10.1007\/s40291-024-00730-0"},{"issue":"7","key":"701_CR135","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovic MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390.","journal-title":"Lancet Neurol"},{"issue":"12","key":"701_CR136","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, Bottcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22(12):1104\u20135.","journal-title":"Lancet Neurol"},{"issue":"11","key":"701_CR137","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron. 2024;112(11):1757\u201363.","journal-title":"Neuron"},{"issue":"2","key":"701_CR138","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-Refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8(2):287\u201394.","journal-title":"J Neuromuscul Dis."},{"issue":"4","key":"701_CR139","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"JI Nishimura","year":"2023","unstructured":"Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118(4):419\u201331.","journal-title":"Int J Hematol"},{"issue":"9","key":"701_CR140","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209\u201319.","journal-title":"J Neurol"},{"key":"701_CR141","doi-asserted-by":"crossref","unstructured":"Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, et al. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. J Neurol. 2024.","DOI":"10.1007\/s00415-024-12569-w"},{"issue":"5","key":"701_CR142","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, et al. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol. 2024;11(5):1338\u201346.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"701_CR143","volume":"16","author":"I Youssef","year":"2024","unstructured":"Youssef I, Abbas MS, Manafi A, Akhondi H, Youssef D. Disseminated cryptococcosis post eculizumab therapy: a case report and literature review. Cureus. 2024;16(4): e58852.","journal-title":"Cureus."},{"key":"701_CR144","first-page":"1","volume":"8","author":"K Emine Rabia","year":"2023","unstructured":"Emine Rabia K, Omer Faruk T, Furkan S, Lazrak ES, Ozen PA, Tuncer A. Probable eculizumab-associated hepatotoxicity in a patient with neuromyelitis optica: a case report. Int J Neurosci. 2023;8:1\u20135.","journal-title":"Int J Neurosci"},{"issue":"5","key":"701_CR145","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775\u201381.","journal-title":"Pediatr Nephrol"},{"key":"701_CR146","doi-asserted-by":"crossref","unstructured":"Ricciardi D, Erra C, Tuccillo F, De Martino BM, Fasolino A, Habetswallner F. Eculizumab in refractory myasthenia gravis: a real-world single-center experience. Neurol Sci. 2024.","DOI":"10.1007\/s10072-024-07861-6"},{"key":"701_CR147","doi-asserted-by":"publisher","first-page":"175628642412616","DOI":"10.1177\/17562864241261602","volume":"17","author":"J Song","year":"2024","unstructured":"Song J, Huan X, Chen Y, Luo Y, Zhong H, Wang Y, et al. The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series. Ther Adv Neurol Disord. 2024;17:17562864241261602.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"701_CR148","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","volume":"269","author":"CMM Strano","year":"2022","unstructured":"Strano CMM, Sorrenti B, Bosco L, Falzone YM, Fazio R, Filippi M. Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. J Neurol. 2022;269(11):6152\u20134.","journal-title":"J Neurol"},{"issue":"2","key":"701_CR149","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/mus.26124","volume":"58","author":"CJJ Yeo","year":"2018","unstructured":"Yeo CJJ, Pleitez MY. Eculizumab in refractory myasthenic crisis. Muscle Nerve. 2018;58(2):E13\u20135.","journal-title":"Muscle Nerve"},{"issue":"11","key":"701_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9547","volume":"12","author":"S Quasthoff","year":"2024","unstructured":"Quasthoff S. Two-decade battle with myasthenia gravis: a breakthrough case report on the long-term success with eculizumab and ravulizumab treatment. Clin Case Rep. 2024;12(11): e9547.","journal-title":"Clin Case Rep."},{"issue":"5","key":"701_CR151","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","volume":"93","author":"C Nelke","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(5):548\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"701_CR152","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","volume":"25","author":"K Schonfelder","year":"2024","unstructured":"Schonfelder K, Kuhne L, Schulte-Kemna L, Kaufeld J, Rohn H, Kribben A, et al. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data. BMC Nephrol. 2024;25(1):202.","journal-title":"BMC Nephrol"},{"issue":"8","key":"701_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024;6(8): 100855.","journal-title":"Kidney Med."},{"issue":"11","key":"701_CR154","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2023012267","volume":"8","author":"S Chonat","year":"2024","unstructured":"Chonat S, Kulagin A, Maschan A, Bartels M, Buechner J, Punzalan R, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024;8(11):2813\u201324.","journal-title":"Blood Adv"},{"key":"701_CR155","doi-asserted-by":"crossref","unstructured":"Mallenahalli Neeekantappa V, Kamath A, Bharathi Rajaduraivelpandian P. Safety profile of monoclonal antibodies and subsequent drug developments in the treatment of paroxysmal nocturnal hemoglobinuria. Medicina (Kaunas). 2024;60(3).","DOI":"10.3390\/medicina60030379"},{"key":"701_CR156","doi-asserted-by":"publisher","first-page":"1378080","DOI":"10.3389\/fneur.2024.1378080","volume":"15","author":"N Katyal","year":"2024","unstructured":"Katyal N, Govindarajan R, Goyal N, Muley S, Muppidi S. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Front Neurol. 2024;15:1378080.","journal-title":"Front Neurol"},{"issue":"1","key":"701_CR157","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol Neuroimmunol Neuroinflamm. 2025;12(1): e200331.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"701_CR158","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","volume":"271","author":"FF Konen","year":"2024","unstructured":"Konen FF, Jendretzky KF, Ratuszny D, Schuppner R, Suhs KW, Pawlitzki M, et al. Ravulizumab in myasthenic crisis: the first case report. J Neurol. 2024;271(5):2898\u2013901.","journal-title":"J Neurol"},{"key":"701_CR159","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, De Bleecker JL, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023;14:1284444.","journal-title":"Front Neurol"},{"key":"701_CR160","doi-asserted-by":"publisher","first-page":"1407418","DOI":"10.3389\/fneur.2024.1407418","volume":"15","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J, Xi J, Tan Y, Gao F, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024;15:1407418.","journal-title":"Front Neurol"},{"issue":"8","key":"701_CR161","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, Wang Q, Zou Z, Yu Y, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"701_CR162","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I, Kolb H, Regev K, Schwartzmann Y, et al. Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol. 2024;271(6):3462\u201370.","journal-title":"J Neurol"},{"key":"701_CR163","doi-asserted-by":"crossref","unstructured":"Konno S, Uchi T, Kihara H, Sugimoto H. Real-world case series of efgartigimod for Japanese generalized myasthenia gravis: well-tailored treatment cycle intervals contribute to sustained symptom control. Biomedicines. 2024;12(6).","DOI":"10.3390\/biomedicines12061214"},{"key":"701_CR164","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","volume":"39","author":"K Horiuchi","year":"2024","unstructured":"Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37\u201341.","journal-title":"Neuromuscul Disord"},{"key":"701_CR165","doi-asserted-by":"publisher","first-page":"1472845","DOI":"10.3389\/fneur.2024.1472845","volume":"15","author":"T Nomura","year":"2024","unstructured":"Nomura T, Imamura M, Imura M, Mizutani H, Ueda M. Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients. Front Neurol. 2024;15:1472845.","journal-title":"Front Neurol"},{"key":"701_CR166","first-page":"9455237","volume":"2024","author":"O Alhaj Omar","year":"2024","unstructured":"Alhaj Omar O, Diel NJ, Gerner ST, Muck A, Huttner HB, Kramer-Best HH. Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis. Case Rep Neurol Med. 2024;2024:9455237.","journal-title":"Case Rep Neurol Med."},{"key":"701_CR167","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X, Jiang Q, Wu Z, Yan C, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024;15:1418503.","journal-title":"Front Immunol"},{"issue":"1","key":"701_CR168","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","volume":"24","author":"H Ohara","year":"2024","unstructured":"Ohara H, Kikutsuji N, Iguchi N, Kinoshita M. Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report. BMC Neurol. 2024;24(1):292.","journal-title":"BMC Neurol"},{"key":"701_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"395","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang SQ, Liu S, Feng S, Chen YB, et al. Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series. J Neuroimmunol. 2024;395: 578431.","journal-title":"J Neuroimmunol"},{"key":"701_CR170","doi-asserted-by":"crossref","unstructured":"Tanaka K, Yoshikawa M, Inoue Y, Tsumura K, Hoshino Y, Shichijo C, et al. Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibodies. Intern Med. 2024;advpub.","DOI":"10.2169\/internalmedicine.3726-24"},{"issue":"1","key":"701_CR171","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Zhang H, Zhao J, Su M, Feng Y, Yuan X, et al. Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep. 2024;14(1):28394.","journal-title":"Sci Rep"},{"issue":"6","key":"701_CR172","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E, Hagenacker T, Meuth SG, Ruck T, et al. Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv Ther. 2024;41(6):2486\u201399.","journal-title":"Adv Ther"},{"issue":"12","key":"701_CR173","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacca","year":"2023","unstructured":"Sacca F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"issue":"2","key":"701_CR174","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38(2):93\u2013104.","journal-title":"CNS Drugs"},{"issue":"12","key":"701_CR175","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","volume":"41","author":"AG Smith","year":"2024","unstructured":"Smith AG, Wolfe GI, Habib AA, Qi CZ, Yang H, Du M, et al. Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis. Adv Ther. 2024;41(12):4628\u201347.","journal-title":"Adv Ther"},{"issue":"7","key":"701_CR176","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","volume":"17","author":"ZF Mao","year":"2010","unstructured":"Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17(7):913\u201321.","journal-title":"Eur J Neurol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00701-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:18:15Z","timestamp":1741835895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00701-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":176,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00701-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"15 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organised by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Concept and planning of the review: L.G. and A.M.; writing of first draft: L.G.; figures: P.D.; and critical revision of the manuscript: all authors. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"L.G. reports no conflicts of interest. P.D. received speaker\u00b4s honoraria from Alexion and UCB. S.H. received speaker\u00b4s honoraria and honoraria for attendance at advisory boards from Alexion, argenx, Roche and UCB. A. M. received speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion, Argenx, Axunio, Destin, Grifols, Hormosan Pharma, Janssen, Merck, Octapharma, UCB and Xcenda. He serves as member of the\u00a0medical advisory board of the German Myasthenia Gravis Society.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analysed for this review article; data that support the findings referenced in this article can be found in their corresponding referenced original study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}